Revance Therapeutics (RVNC) Sees Strong Upside on Volume
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Revance Therapeutics (NASDAQ: RVNC) is seeing notable upside Friday. Shares are up 18% on volume that is running 10x normal. It is unclear today's driver.
Analyst Louise Chen at Guggenheim recently noted upcoming potential catalysts include: 1) 2H16 - Report top-line data for RT002 in Cervical Dystonia; 2) 2H16 - Initiate Phase 3 program for RT002 for Glabellar Lines; 3) 2H16 - Announce an additional indication for RT002; 4) '17 - RT002, Phase 3 data for Glabellar Lines; 5) '17 - More data on Cervical Dystonia and additional indication; 6) '20 - RT002, Approval and Launch for Glabellar Lines; and 7) '22/'23 - RT002, Cervical Dystonia.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Advises Patients With St. Jude Medical (STJ) Heart Implants to Continue Using Devices - Reuters
- Options with increasing volume: RRC VIP GRUB CALL BEAV TMUS WEN VIP AEO ETFC GNW
- AK Steel (AKS) October weekly volatility increases on more puts than calls into Q3
Create E-mail Alert Related CategoriesFDA, Momentum Movers, Trader Talk
Related EntitiesLouise Chen, Guggenheim
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!